Rockwell Medical (RMTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The annual meeting will be held virtually on June 12, 2026, with stockholders voting on director elections, executive compensation, auditor ratification, and a reverse stock split amendment.
Only stockholders of record as of April 16, 2026, are entitled to vote, with a majority quorum required.
The Board recommends voting in favor of all proposals, including the reverse stock split to maintain Nasdaq listing compliance.
Voting matters and shareholder proposals
Stockholders will vote to elect two Class II directors for three-year terms, approve executive compensation on an advisory basis, ratify EisnerAmper LLP as auditor for 2026, and approve a reverse stock split amendment.
The reverse stock split ratio may range from 1-for-2 to 1-for-10, with the Board authorized to select the ratio and timing.
Stockholders may submit proposals for the 2027 meeting by December 31, 2026.
Board of directors and corporate governance
The Board is divided into three classes, with staggered terms; independence is maintained per Nasdaq rules.
Board leadership is separated between the Chairman and CEO roles.
Committees include Audit, Compensation, and Nominating and Governance, each with defined charters and responsibilities.
Directors are subject to stock ownership guidelines and anti-hedging/pledging policies.
Latest events from Rockwell Medical
- Q2 2026 delivered 11% sales growth, margin gains, and improved profitability with strong guidance.RMTI
Q2 2026 - All agenda items, including a reverse stock split, were approved by stockholders.RMTI
AGM 2026 - Shareholders are urged to approve a reverse stock split to help maintain Nasdaq listing.RMTI
Proxy filing - Q1 2026 sales fell 8% to $17.3M, but margin improved and 2026 guidance targets profitability.RMTI
Q1 2026 - Key votes include director elections, executive pay, auditor ratification, and a reverse stock split.RMTI
Proxy filing - Strong FY'25 results and margin gains support ambitious growth and profitability targets.RMTI
Investor presentation - Gross margin hit 21% in Q4 2025, with positive adjusted EBITDA and strong cash flow.RMTI
Q4 2025 - Q3 2024 saw record sales, profitability, and raised guidance despite customer concentration risk.RMTI
Q3 2024 - Q1 2025 sales dropped 17% on customer loss, but margin improved and guidance reaffirmed.RMTI
Q1 2025